Radleys Discovery Technologies

Aureus Strengthens Executive Management Team

Date Posted: Thursday, September 07, 2006

Print Email to a friend

Aureus Pharma has announced the appointment of Jason Theodosiou as Chief Operating Officer and also as member of the Aureus Board of Directors.

In this new position, Dr. Theodosiou will be responsible for directing the company’s worldwide operations including commercial efforts.

Dr. Theodosiou brings extensive experience in the Life Science Informatics industry where he has held various senior management positions.

Most recently he was Vice President for Global Business at Elsevier MDL and at Lion Biosciences.

He also has held positions of General Manager for European Operations at EMAX/SciQUEST. He holds a BSc/MSc and Ph.D. in Organic Chemistry from the University of Aix-Marseilles as well as an Executive MBA from the ESCP Business School of Paris

"We are very excited to welcome Jason Theodosiou to Aureus Pharma," said Dr. Andre Michel, Aureus’ CEO.

"His leadership and business experience will be important assets to both Aureus Pharma and our customers."

"We are looking forward to his contributions to the strategic directions and executive management of our company."

"Aureus Pharma is a dynamic and innovative company with a high quality knowledge database product portfolio and a recognized expertise in the market," said Theosodiou whose expertise is delivering highly customer focused solutions to the drug discovery industry.

"I am pleased to join the company and I look forward to further growing the company’s global operations and customer base."

Further Information: http://www.aureus-pharma.com

Related Products

Aureus Pharma releases AurSCOPE® Kinase Knowledge Database
The database contains biological activity data mined from scientific journals and patents.

Related news from our archive

Aureus Pharma Licenses AurWEB to Origenis
AurWEB is designed to allow access to all of Aureus’ knowledge databases, which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug interactions and hERG.

Aureus licenses AurSCOPE Ion Channel Knowledgebase to Xention
Access to this knowledge database will help Xention to use the selectivity profile and ADMET properties of existing drugs.

Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
Aureus’ ADME/DDI and hERG knowledge databases contain data which can help assess the safety of a potential pharmaceutical candidate.